Production (Stage)
Aligos Therapeutics, Inc.
ALGS
$8.36
-$0.43-4.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 152.45% | -326.55% | -480.54% | 114.52% | -24.99% |
| Total Depreciation and Amortization | -71.09% | 0.60% | 9.34% | 116.31% | -63.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -195.10% | 3,693.54% | 105.71% | -268.94% | 264.67% |
| Change in Net Operating Assets | -883.33% | 87.74% | -177.40% | 174.83% | -1,775.09% |
| Cash from Operations | -13.62% | 8.45% | -3.12% | 14.30% | -0.39% |
| Capital Expenditure | -53.57% | -7.69% | -271.43% | 89.86% | -885.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -320.12% | 91.86% | -73.94% | 145.16% | -- |
| Cash from Investing | -320.64% | 92.08% | -74.00% | 145.12% | -1,266,214.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -760.00% | 68.75% | 15.79% | -375.00% |
| Issuance of Common Stock | 72,572.86% | 13,900.00% | -99.66% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 104,788.66% | 2,525.00% | -101.42% | 1,578.95% | -100.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,106.84% | 117.16% | -146.71% | 118.65% | -270.68% |